{"entity":{"id":"krascendo-1","kind":"trial","name":"Krascendo 1","aka":[],"tldr":"The first head-to-head trial among KRAS drugs: Roche's divarasib beat the two approved pills on progression and survival.","summary":"Krascendo 1, trial NCT06497556 sponsored by Roche, is the first head-to-head trial among KRAS drugs, comparing divarasib with sotorasib or adagrasib in previously treated KRAS G12C-mutant non-small-cell lung cancer. Roche announced on 2 July 2026 that divarasib showed superior progression-free survival by blinded review and superior overall survival at an interim analysis against the two approved inhibitors, with full data expected at a 2026 congress from a trial of 338 patients. OnCo links it to KRAS as a target and to all three drugs, and notes that Krascendo 2 tests divarasib with pembrolizumab in the first line. Because the numbers are pending and this is the first such comparison, there is no independent replication, and whether a more potent G12C inhibitor changes the modest picture left by CodeBreaK 200 and KRYSTAL-12 is the open question. Divarasib has its own page.","status":"positive","asOf":"2026-09-06","links":[{"label":"ClinicalTrials.gov NCT06497556","url":"https://clinicaltrials.gov/study/NCT06497556"},{"label":"Roche release","url":"https://www.roche.com/media/releases/med-cor-2026-07-02"}],"tags":[],"related":[],"cancers":["nsclc","kras-g12c-nsclc"],"sections":[],"technologies":["kras-inhibitors"],"targets":["kras"],"drugs":["divarasib","sotorasib","adagrasib"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06497556","phase":"3","setting":"Previously treated KRAS G12C NSCLC: divarasib vs sotorasib or adagrasib","sponsor":"Roche","result":"Superior PFS and OS vs approved G12C inhibitors (topline, July 2026).","started":"2024-09-23","startedType":"actual","yearReported":2026,"enrolled":338,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival (BICR)","primary":true,"unit":"months","arms":[{"name":"Divarasib","note":"Primary endpoint met with a statistically significant, clinically meaningful improvement per the sponsor (topline 2 July 2026); medians and hazard ratio pending presentation."},{"name":"Sotorasib or adagrasib"}],"source":"https://clinicaltrials.gov/study/NCT06497556"},{"endpoint":"Overall survival (interim)","unit":"months","arms":[{"name":"Divarasib","note":"Statistically significant OS improvement at the interim analysis per the sponsor; numbers pending."},{"name":"Sotorasib or adagrasib"}],"source":"https://clinicaltrials.gov/study/NCT06497556"}],"replication":"Topline reported July 2026; numbers pending presentation. First head-to-head phase 3 among KRAS G12C inhibitors, so no independent replication yet."},"route":"/trials/krascendo-1/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"drug":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/"},{"id":"divarasib","kind":"drug","name":"Divarasib","route":"/drugs/divarasib/"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"roadmap":[{"id":"targeted-therapy-roadmap","kind":"roadmap","name":"Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall","route":"/roadmaps/targeted-therapy-roadmap/"}]}}